Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients

Cancer Science

Volumn 102, Issue 2, 2011, Pages 478-483

  Chuah, Benjamin ^a   Goh, Boon Cher ^a,b   Lee, Soo Chin ^a,b   Soong, Richie ^b   Lau, Fayce ^a   Mulay, Marilyn ^c   Dinolfo, Melissa ^c   Lim, Siew Eng ^a   Soo, Ross ^a   Furuie, Taro ^d   Saito, Kaku ^d   Zergebel, Christopher ^d   Rosen, Lee S ^c  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c Premiere Oncology   (United States)

^d Taiho Pharma USA Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ALANINE DERIVATIVE; ANTINEOPLASTIC AGENT; COTININE; CYTOCHROME P450 2A6; FLUORO BETA ALANINE; FLUOROURACIL; GIMERACIL; NICOTINE; OXONIC ACID; TEGAFUR; UNCLASSIFIED DRUG; URACIL DERIVATIVE;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASIAN; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CAUCASIAN; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; EVENING DOSAGE; FACIAL CELLULITIS; FATIGUE; FEMALE; FLUID THERAPY; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GENOTYPE; HAND FOOT SYNDROME; HUMAN; LARYNX EDEMA; LUNG EMBOLISM; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MOUTH; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHARMACODYNAMICS; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEPSIS; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG COMBINATIONS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FAR EAST; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; OXONIC ACID; PHENOTYPE; TEGAFUR;

EID: 79952082092     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01793.x     Document Type: Article

References (26)

1. Shirasaka T, Shimamato Y, Ohshimo H et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996; 7: 548-57.
2. Sakuramoto S, Sasako M, Yamaguchi T et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Eng J Med 2007; 357: 1810-20.
3. Hirata K, Horikoshi N, Aiba K et al. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 1999; 5: 2000-5.
4. van Groeningen CJ, Peters GJ, Schornagel JH et al. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol 2000; 18: 2772-9.
5. Hoff PM, Saad ED, Ajani JA et al. Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28days in patients with solid tumors. Clin Cancer Res 2003; 9: 134-42.
6. Ikeda K, Yoshisue K, Matsushima E et al. Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro. Clin Cancer Res 2000; 6: 4409-15.
7. Yoshida R, Nakajima M, Nishimura K, Tokudome S, Kwon JT, Yokoi T. Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clin Pharmacol Ther 2003; 74: 69-76.
8. Malaiyandi V, Sellers EM, Tyndale RF. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin Pharmacol Ther 2005; 77: 145-58.
9. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987; 47: 2203-6.
10. Messina ES, Tyndale RF, Sellers EM. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther 1997; 282: 1608-14.
11. Nakajima M, Kwon JT, Tanaka N et al. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Clin Pharmacol Ther 2001; 69: 72-8.
12. Peters GJ, Noordhuis P, Van Groeningen CJ et al. The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors. Clin Cancer Res 2004; 10: 4072-6.
13. Pitarque M, von Richter O, Rodriguez-Antona C, Wang J, Oscarson M, Ingelman-Sundberg M. A nicotine C-oxidase gene (CYP2A6) polymorphism important for promoter activity. Hum Mutat 2004; 23: 258-66.
14. Kalow W. Interethnic differences in drug response. In: Kalow W, Meyer UA, Tyndale RF, eds. Pharmacogenomics. New York, NY: Marcel Dekker, 2001; 109-34.
15. Burroughs VJ, Maxey RW, Levy RA. Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment. J Natl Med Assoc 2002; 94: 1-26.
16. Liu GT. Effects of some compounds isolated from Chinese medicinal herbs on hepatic microsomal cytochrome P-450 and their potential biological consequences. Drug Metab Rev 1991; 23: 439-65.
17. Fujita K, Yamamoto W, Endo S et al. CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1. Cancer Sci 2008; 99: 1049-54.
18. Jhee SS, Burm JP, Gill MA. Comparison of aminoglycoside pharmacokinetics in Asian, Hispanic, and Caucasian patients by using population pharmacokinetic methods. Antimicrob Agents Chemother 1994; 38: 2073-7.
19. Goh BC, Lee SC, Wang LZ et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 2002; 20: 3683-90.
20. Mathijssen RH, de Jong FA, van Schaik RH et al. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst 2004; 96: 1585-92.
21. Kaida Y, Inui N, Suda T, Nakamura H, Watanabe H, Chida K. The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer. Clin Pharmacol Ther 2008; 83: 589-94.
22. Ariyoshi N, Sawamura Y, Kamataki T. A novel single nucleotide polymorphism altering stability and activity of CYP2a6. Biochem Biophys Res Commun 2001; 281: 810-4.
23. McCollum AD, Catalano PJ, Haller DG et al. Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst 2002; 94: 1160-7.
24. Haller DG, Cassidy J, Clarke SJ et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 2008; 26: 2118-23.
25. Shirao K, Hoff PM, Ohtsu A et al. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. J Clin Oncol 2004; 22: 3466-74.
26. Marsh S, Collie-Duguid ES, Li T, Liu X, McLeod HL. Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 1999; 58: 310-2.